Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:EQ NASDAQ:RLMD NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$18.35-8.4%$22.82$2.15▼$28.44$702.93M1.22310,102 shs414,098 shsEQEquillium$2.94-7.3%$2.20$0.27▼$3.45$200.43M1.771.04 million shs1.14 million shsRLMDRelmada Therapeutics$5.95-5.7%$7.07$0.52▼$8.00$661.86M0.39952,599 shs1.26 million shsSLDBSolid Biosciences$6.70-7.5%$7.41$3.79▼$8.87$712.78M2.431.09 million shs701,826 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+5.96%-0.94%-21.24%-3.38%+721.68%EQEquillium+1.93%+11.62%+53.14%+79.10%+759.08%RLMDRelmada Therapeutics-0.32%-12.97%-14.15%+41.80%+755.13%SLDBSolid Biosciences+5.69%+2.40%+4.93%+7.26%+88.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$18.35-8.4%$22.82$2.15▼$28.44$702.93M1.22310,102 shs414,098 shsEQEquillium$2.94-7.3%$2.20$0.27▼$3.45$200.43M1.771.04 million shs1.14 million shsRLMDRelmada Therapeutics$5.95-5.7%$7.07$0.52▼$8.00$661.86M0.39952,599 shs1.26 million shsSLDBSolid Biosciences$6.70-7.5%$7.41$3.79▼$8.87$712.78M2.431.09 million shs701,826 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience+5.96%-0.94%-21.24%-3.38%+721.68%EQEquillium+1.93%+11.62%+53.14%+79.10%+759.08%RLMDRelmada Therapeutics-0.32%-12.97%-14.15%+41.80%+755.13%SLDBSolid Biosciences+5.69%+2.40%+4.93%+7.26%+88.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.70Moderate Buy$35.2591.43% UpsideEQEquillium 2.78Moderate Buy$7.57156.22% UpsideRLMDRelmada Therapeutics 2.71Moderate Buy$12.00102.19% UpsideSLDBSolid Biosciences 2.92Moderate Buy$16.82150.08% UpsideCurrent Analyst Ratings BreakdownLatest EQ, RLMD, ANRO, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026SLDBSolid Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.005/28/2026EQEquillium Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$7.005/28/2026EQEquillium Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$5.005/28/2026EQEquillium Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/28/2026EQEquillium Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$1.00 ➝ $6.005/27/2026ANROAlto Neuroscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/22/2026ANROAlto Neuroscience Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/18/2026ANROAlto Neuroscience Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $36.005/14/2026ANROAlto Neuroscience WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$21.00 ➝ $24.005/13/2026SLDBSolid Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$17.00 ➝ $18.005/13/2026SLDBSolid Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$4.87 per shareN/AEQEquilliumN/AN/AN/AN/A$0.47 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASLDBSolid BiosciencesN/AN/AN/AN/A$2.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$63.24M-$2.42N/AN/AN/AN/A-47.22%-38.81%8/12/2026 (Estimated)EQEquillium-$22.40M-$0.32N/AN/AN/AN/A-61.43%-53.72%8/13/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)SLDBSolid Biosciences-$174.32M-$1.95N/AN/AN/AN/A-73.42%-61.13%8/11/2026 (Estimated)Latest EQ, RLMD, ANRO, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ANROAlto Neuroscience-$0.56-$0.80-$0.24-$0.80N/AN/A5/13/2026Q1 2026EQEquillium-$0.04-$0.06-$0.02-$0.06N/AN/A5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/12/2026Q1 2026SLDBSolid Biosciences-$0.40-$0.52-$0.12-$0.52N/AN/A3/25/2026Q4 2025EQEquillium-$0.07-$0.04+$0.03-$0.04N/AN/A3/19/2026Q4 2025RLMDRelmada Therapeutics-$0.14-$0.27-$0.13-$0.27N/AN/A3/19/2026Q4 2025SLDBSolid Biosciences-$0.51-$0.50+$0.01-$0.53N/AN/A3/16/2026Q4 2025ANROAlto Neuroscience-$0.56-$0.45+$0.11-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.0720.5220.52EQEquilliumN/A18.6218.62RLMDRelmada TherapeuticsN/A18.2518.25SLDBSolid BiosciencesN/A13.1013.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AEQEquillium27.05%RLMDRelmada Therapeutics45.24%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.25%EQEquillium17.84%RLMDRelmada Therapeutics14.50%SLDBSolid Biosciences2.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A35.09 million31.15 millionN/AEQEquillium4063.23 million51.95 millionNot OptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableSLDBSolid Biosciences10098.45 million95.83 millionOptionableEQ, RLMD, ANRO, and SLDB HeadlinesRecent News About These CompaniesSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comSolid Biosciences to Participate at Upcoming Investor ConferencesJune 1, 2026 | globenewswire.comJ.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)May 24, 2026 | theglobeandmail.comWhere Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?May 20, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)May 14, 2026 | theglobeandmail.comSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 12, 2026 | globenewswire.comSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyMay 7, 2026 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyApril 30, 2026 | globenewswire.comSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyApril 28, 2026 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Stryker (SYK), Solid Biosciences (SLDB)April 17, 2026 | theglobeandmail.comSolid Biosciences Adjusts Board Classes in Governance MoveApril 12, 2026 | theglobeandmail.comSolid Biosciences to Participate at Upcoming Investor ConferencesApril 7, 2026 | globenewswire.comJ.P. Morgan Issues a Buy Rating on Solid Biosciences (SLDB)March 27, 2026 | theglobeandmail.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Mereo Biopharma Group Plc (MREO)March 22, 2026 | theglobeandmail.comGuggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendationMarch 21, 2026 | msn.comSolid Bio wins new buy at Guggenheim on lead assetMarch 20, 2026 | msn.comSolid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 20, 2026 | finanznachrichten.deSolid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 19, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB)March 17, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSilicon Shake-Up: The AI Trade Is Moving Beyond NVIDIABy Jeffrey Neal Johnson | May 21, 2026From High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 2026Why OpenAI’s IPO Plans Could Be a Massive Win for MicrosoftBy Chris Markoch | May 13, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026Amazon vs. Alibaba: One Is Clearly The Better Value Play right NowBy Sam Quirke | May 14, 2026EQ, RLMD, ANRO, and SLDB Company DescriptionsAlto Neuroscience NYSE:ANRO$18.35 -1.68 (-8.38%) Closing price 03:59 PM EasternExtended Trading$18.20 -0.15 (-0.83%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Equillium NASDAQ:EQ$2.94 -0.23 (-7.26%) Closing price 04:00 PM EasternExtended Trading$2.97 +0.03 (+1.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Relmada Therapeutics NASDAQ:RLMD$5.95 -0.36 (-5.71%) Closing price 04:00 PM EasternExtended Trading$5.95 0.00 (0.00%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Solid Biosciences NASDAQ:SLDB$6.70 -0.54 (-7.46%) Closing price 04:00 PM EasternExtended Trading$6.90 +0.20 (+2.99%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
